New Agents in Acute Myeloid Leukemia and Other Myeloid Disorders

Farhad Ravandi, Hagop Kantarjian, Francis Giles, Jorge Cortes

Research output: Contribution to journalReview article

Abstract

Over the past several decades, improvements in chemotherapeutic agents and supportive care have resulted in significant progress in treating patients with acute myeloid leukemia (AML). More recently, advances in understanding the biology of AML have resulted in the identification of new therapeutic targets. The success of all-trans-retinoic acid in acute promyelocytic leukemia and of imatinib mesylate in chronic myeloid leukemia have demonstrated that targeted therapy may be more effective and less toxic when well defined targets are available. At the same time, understanding mechanisms of drug resistance and means to overcome them has led to modification of some of the existing cytotoxic agents. Rational design and conduct of clinical trials is necessary to ensure that the full potential of these new agents is realized.

Original languageEnglish (US)
Pages (from-to)441-454
Number of pages14
JournalCancer
Volume100
Issue number3
DOIs
StatePublished - Feb 1 2004
Externally publishedYes

Fingerprint

Acute Myeloid Leukemia
Acute Promyelocytic Leukemia
Poisons
Cytotoxins
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Tretinoin
Drug Resistance
Clinical Trials
Therapeutics
Imatinib Mesylate

Keywords

  • Acute myeloid leukemia
  • New agents
  • New targets
  • Therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

New Agents in Acute Myeloid Leukemia and Other Myeloid Disorders. / Ravandi, Farhad; Kantarjian, Hagop; Giles, Francis; Cortes, Jorge.

In: Cancer, Vol. 100, No. 3, 01.02.2004, p. 441-454.

Research output: Contribution to journalReview article

Ravandi, F, Kantarjian, H, Giles, F & Cortes, J 2004, 'New Agents in Acute Myeloid Leukemia and Other Myeloid Disorders', Cancer, vol. 100, no. 3, pp. 441-454. https://doi.org/10.1002/cncr.11935
Ravandi, Farhad ; Kantarjian, Hagop ; Giles, Francis ; Cortes, Jorge. / New Agents in Acute Myeloid Leukemia and Other Myeloid Disorders. In: Cancer. 2004 ; Vol. 100, No. 3. pp. 441-454.
@article{96894d73daee40ab85e81dd06ae9e488,
title = "New Agents in Acute Myeloid Leukemia and Other Myeloid Disorders",
abstract = "Over the past several decades, improvements in chemotherapeutic agents and supportive care have resulted in significant progress in treating patients with acute myeloid leukemia (AML). More recently, advances in understanding the biology of AML have resulted in the identification of new therapeutic targets. The success of all-trans-retinoic acid in acute promyelocytic leukemia and of imatinib mesylate in chronic myeloid leukemia have demonstrated that targeted therapy may be more effective and less toxic when well defined targets are available. At the same time, understanding mechanisms of drug resistance and means to overcome them has led to modification of some of the existing cytotoxic agents. Rational design and conduct of clinical trials is necessary to ensure that the full potential of these new agents is realized.",
keywords = "Acute myeloid leukemia, New agents, New targets, Therapy",
author = "Farhad Ravandi and Hagop Kantarjian and Francis Giles and Jorge Cortes",
year = "2004",
month = "2",
day = "1",
doi = "10.1002/cncr.11935",
language = "English (US)",
volume = "100",
pages = "441--454",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - New Agents in Acute Myeloid Leukemia and Other Myeloid Disorders

AU - Ravandi, Farhad

AU - Kantarjian, Hagop

AU - Giles, Francis

AU - Cortes, Jorge

PY - 2004/2/1

Y1 - 2004/2/1

N2 - Over the past several decades, improvements in chemotherapeutic agents and supportive care have resulted in significant progress in treating patients with acute myeloid leukemia (AML). More recently, advances in understanding the biology of AML have resulted in the identification of new therapeutic targets. The success of all-trans-retinoic acid in acute promyelocytic leukemia and of imatinib mesylate in chronic myeloid leukemia have demonstrated that targeted therapy may be more effective and less toxic when well defined targets are available. At the same time, understanding mechanisms of drug resistance and means to overcome them has led to modification of some of the existing cytotoxic agents. Rational design and conduct of clinical trials is necessary to ensure that the full potential of these new agents is realized.

AB - Over the past several decades, improvements in chemotherapeutic agents and supportive care have resulted in significant progress in treating patients with acute myeloid leukemia (AML). More recently, advances in understanding the biology of AML have resulted in the identification of new therapeutic targets. The success of all-trans-retinoic acid in acute promyelocytic leukemia and of imatinib mesylate in chronic myeloid leukemia have demonstrated that targeted therapy may be more effective and less toxic when well defined targets are available. At the same time, understanding mechanisms of drug resistance and means to overcome them has led to modification of some of the existing cytotoxic agents. Rational design and conduct of clinical trials is necessary to ensure that the full potential of these new agents is realized.

KW - Acute myeloid leukemia

KW - New agents

KW - New targets

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=1642453610&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1642453610&partnerID=8YFLogxK

U2 - 10.1002/cncr.11935

DO - 10.1002/cncr.11935

M3 - Review article

C2 - 14745859

AN - SCOPUS:1642453610

VL - 100

SP - 441

EP - 454

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 3

ER -